Abstract
Tamoxifen is one of the modalities in the treatment for breast cancer, especially in postmenopausal patients. It acts primarily as an anti-estrogenic agent, due to its cytoplasmic estrogen receptor binding capacity. However, the same also exerts a mild estrogenic effect. Here with a case of ER positive carcinoma breast treated with Tamoxifen for 5 years, presented as post- menopausal bleeding per vaginum, showed an enhanced mass occupying the endometrial cavity, measuring >30mm is presented. Total hysterectomy was done.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Evolution of Medical and Dental Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
